Edition:
United States

Profile: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,110.00GBp
27 Feb 2017
Change (% chg)

1.00 (+0.05%)
Prev Close
2,109.00
Open
2,105.00
Day's High
2,118.00
Day's Low
2,085.00
Volume
409,408
Avg. Vol
751,146
52-wk High
2,703.00
52-wk Low
1,575.00

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.

Company Address

Hikma Pharmaceuticals PLC

13 Hanover Square
LONDON     W1S 1HL
P: +4420.73992760
F: +4420.73992761

Company Web Links